青少年和青年原发性血小板增多症与真性红细胞增多症的治疗影响
这项回顾性研究纳入25岁前诊断的348例原发性血小板增多症或真性红细胞增多症患者(278例原发性血小板增多症,70例真性红细胞增多症),中位年龄20岁,评估并发症发生率及细胞减灭药物对结局的影响。血栓事件发生率为每100患者年1.9次,继发性骨髓纤维化发生率为每100患者年0.7次;干扰素作为一线治疗较其他治疗或无细胞减灭显著改善无骨髓纤维化生存(p=0.046)。
要点
- 血栓事件发生率为每100患者年1.9次,细胞减灭药物未降低该风险。
- 继发性骨髓纤维化发生率为每100患者年0.7次。
- 干扰素一线治疗较其他治疗或无细胞减灭显著改善无骨髓纤维化生存(p=0.046)。
核心结论
- 细胞减灭未影响血栓事件,但早期使用干扰素可降低继发性骨髓纤维化风险,这些发现支持在青少年和青年原发性血小板增多症与真性红细胞增多症患者中使用干扰素以减轻继发性骨髓纤维化风险。
研究设计与样本
- 回顾性研究,纳入25岁前诊断的原发性血小板增多症和真性红细胞增多症患者348例(278例原发性血小板增多症,70例真性红细胞增多症),中位年龄20岁,评估并发症发生率及细胞减灭药物对结局的影响。
主要发现
- 血栓事件发生率为每100患者年1.9次。
- 血栓形成的危险因素包括白细胞计数升高(>11 × 10^9/L)(HR:2.7,p = 0.012)和诊断时无脾肿大(HR:5.7,p = 0.026),而细胞减灭药物未降低该风险。
- 继发性骨髓纤维化发生率为每100患者年0.7次。
- CALR突变(HR:6.0,p < 0.001)和血栓史(HR:3.8,p = 0.015)与继发性骨髓纤维化风险相关。
- 干扰素作为一线治疗较其他治疗或无细胞减灭显著改善无骨髓纤维化生存(p = 0.046)。
临床怎么用
- 作者认为,这些发现支持在青少年和青年原发性血小板增多症与真性红细胞增多症患者中使用干扰素以减轻继发性骨髓纤维化风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Essential thrombocythemia (ET) and polycythemia vera (PV) are rare in adolescent and young adult (AYA). These conditions, similar to those in older patients, are linked with thrombotic complications and the potential progression to secondary myelofibrosis (sMF). This retrospective study of ET and PV patients diagnosed before age 25 evaluated complication rates and impact of cytoreductive drugs on outcomes. Among 348 patients (278 ET, 70 PV) with a median age of 20 years, the of thrombotic events was 1.9 per 100 patient-years. Risk factors for thrombosis included elevated white blood cell count (>11 × 109/L) (HR: 2.7, p = 0.012) and absence of splenomegaly at diagnosis (HR: 5.7, p = 0.026), while cytoreductive drugs did not reduce this risk. The incidence of sMF was 0.7 per 100 patient-years. CALR mutation (HR: 6.0, p < 0.001) and a history of thrombosis (HR: 3.8, p = 0.015) were associated with sMF risk. Interferon as a first-line treatment significantly improved myelofibrosis-free survival compared to other treatments or the absence of cytoreduction (p = 0.046). Although cytoreduction did not affect thrombotic event, early interferon use reduced sMF risk. These findings support interferon use to mitigate sMF risk in AYA ET and PV patients.
引用
- Beauverd Y, Ianotto JC, Thaw KH, et al. Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera. Leukemia. 2025. PMID: 40074852. doi:10.1038/s41375-025-02545-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。